Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
58.92
-1.67 (-2.75%)
Streaming Delayed Price
Updated: 1:51 PM EDT, May 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
89
90
Next >
1 Safe-and-Steady Stock with Exciting Potential and 2 to Brush Off
July 14, 2025
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Via
StockStory
Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today
July 11, 2025
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other...
Via
StockStory
Topics
ETFs
Intellectual Property
Stocks
Top S&P500 movers in Friday's session
↗
July 11, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session.
Via
Chartmill
Price Over Earnings Overview: Bristol-Myers Squibb
↗
July 04, 2025
Via
Benzinga
What's going on in today's session: S&P500 movers
↗
July 11, 2025
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via
Chartmill
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?
↗
July 11, 2025
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with...
Via
Benzinga
What's going on in today's session: S&P500 gap up and gap down stocks
↗
July 11, 2025
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via
Chartmill
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
↗
July 11, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via
Benzinga
Topics
Government
World Trade
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
↗
July 11, 2025
Via
The Motley Fool
Topics
Intellectual Property
Why Is AbbVie Stock Trading Higher On Thursday?
↗
July 10, 2025
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
Via
Benzinga
What Analysts Are Saying About Bristol-Myers Squibb Stock
↗
July 10, 2025
Via
Benzinga
Warren Buffett's Quiet Dividend Play: 9 High-Yield Stocks Held By A Berkshire Subsidiary
↗
July 09, 2025
Warren Buffett is indirectly invested in high-dividend yield stocks via Berkshire Hathaway Inc.'s subsidiary New England Asset Management.
Via
Benzinga
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)
July 08, 2025
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch.
↗
July 07, 2025
Via
The Motley Fool
Topics
ETFs
Regulatory Compliance
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
↗
July 03, 2025
Via
Benzinga
Is Pfizer Stock a Yield Trap?
↗
July 03, 2025
Via
The Motley Fool
Topics
Intellectual Property
10 Health Care Stocks With Whale Alerts In Today's Session
↗
July 02, 2025
Via
Benzinga
3 Large-Cap Stocks Skating on Thin Ice
July 02, 2025
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...
Via
StockStory
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
↗
June 30, 2025
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
Via
Benzinga
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
↗
June 28, 2025
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors.
Via
Chartmill
FDA Eases Rules For Bristol Myers' Cell Therapies For Blood Cancers
↗
June 27, 2025
FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements.
Via
Benzinga
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
June 26, 2025
From
Bristol Myers Squibb
Via
Business Wire
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
↗
June 26, 2025
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Via
Investor's Business Daily
Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drug
↗
June 25, 2025
Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.
Via
Benzinga
Topics
Fraud
Lawsuit
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Stock Worth Considering
↗
June 23, 2025
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers strong profitability, a high dividend yield, and an attractive valuation, making it a potential pick for value investors.
Via
Chartmill
Q1 Rundown: Royalty Pharma (NASDAQ:RPRX) Vs Other Branded Pharmaceuticals Stocks
June 18, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Q1 Earnings Outperformers: Eli Lilly (NYSE:LLY) And The Rest Of The Branded Pharmaceuticals Stocks
June 18, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at branded pharmaceuticals stocks, starting...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Bristol Myers Squibb Announces Dividend
June 17, 2025
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers’ Cancer Drug Data Fuels Retail Buzz, But Bearish Sentiment Lingers
↗
June 16, 2025
The new data showed that its lymphoma therapy, Breyanzi, delivered a 95.5% response rate and strong 24-month survival outcomes in a Phase 2 trial.
Via
Stocktwits
Top S&P500 movers in Monday's session
↗
June 16, 2025
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via
Chartmill
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
89
90
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
